vidarabine has been researched along with Metabolic Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Downey, M; Gupta, A; Jennissen, C; Lund, TC; Miller, WP; Orchard, PJ; Shanley, R; Smith, AR | 1 |
| Ahmed, N; Bollard, CM; Brenner, MK; Carrum, G; Gottschalk, S; Heslop, HE; Krance, RA; Leung, KS; Myers, GD; Rosenblatt, H | 1 |
2 other study(ies) available for vidarabine and Metabolic Diseases
| Article | Year |
|---|---|
Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Metabolic Diseases; Myeloablative Agonists; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2020 |
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Living Donors; Lymphocyte Transfusion; Male; Metabolic Diseases; Prospective Studies; Retrospective Studies; Severe Combined Immunodeficiency; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Vidarabine | 2008 |